PRPH Fundamental Analysis - PROPHASE LABS INC

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to PRPH. PRPH was compared to 196 industry peers in the Pharmaceuticals industry. PRPH may be in some trouble as it scores bad on both profitability and health. PRPH is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PRPH has reported negative net income.

In the past year PRPH has reported a negative cash flow from operations.

In multiple years PRPH reported negative net income over the last 5 years.

In the past 5 years PRPH reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of PRPH (-126.93%) is worse than 80.61% of its industry peers.

PRPH has a Return On Equity of -466.63%. This is in the lower half of the industry: PRPH underperforms 76.53% of its industry peers.

		Industry Rank	Sector Rank
ROA	-126.93%
ROE	-466.63%
ROIC	N/A

ROA(3y)-27.2%

ROA(5y)-16.24%

ROE(3y)-243.55%

ROE(5y)-147.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRPH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, PRPH has more shares outstanding

PRPH has more shares outstanding than it did 5 years ago.

The debt/assets ratio for PRPH is higher compared to a year ago.

2.2 Solvency

PRPH has an Altman-Z score of -4.50. This is a bad value and indicates that PRPH is not financially healthy and even has some risk of bankruptcy.

PRPH has a Altman-Z score (-4.50) which is comparable to the rest of the industry.

PRPH has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.45, PRPH perfoms like the industry average, outperforming 41.84% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.45
Debt/FCF	N/A
Altman-Z	-4.5

ROIC/WACCN/A

WACC14.95%

2.3 Liquidity

A Current Ratio of 0.96 indicates that PRPH may have some problems paying its short term obligations.

PRPH's Current ratio of 0.96 is on the low side compared to the rest of the industry. PRPH is outperformed by 82.14% of its industry peers.

PRPH has a Quick Ratio of 0.96. This is a bad value and indicates that PRPH is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.93, PRPH is not doing good in the industry: 75.51% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.96
Quick Ratio	0.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PRPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.99%.

PRPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.65%.

Measured over the past years, PRPH shows a decrease in Revenue. The Revenue has been decreasing by -7.32% on average per year.

EPS 1Y (TTM)-80.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.67%

Revenue 1Y (TTM)-80.65%

Revenue growth 3Y-55.91%

Revenue growth 5Y-7.32%

Sales Q2Q%-49.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y75.59%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year64.06%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PRPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PRPH does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROPHASE LABS INC

NASDAQ:PRPH (9/23/2025, 4:00:00 PM)

0.4473

0 (-0.58%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-13 2025-08-13/bmo

Earnings (Next)11-11 2025-11-11

Inst Owners11.59%

Inst Owner Change-46.98%

Ins Owners7.99%

Ins Owner Change0%

Market Cap18.58M

Analysts82.86

Price Target16.32 (3548.56%)

Short Float %2.49%

Short Ratio0.13

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)25.93%

Min EPS beat(2)23.75%

Max EPS beat(2)28.1%

EPS beat(4)2

Avg EPS beat(4)-363.87%

Min EPS beat(4)-957.84%

Max EPS beat(4)28.1%

EPS beat(8)3

Avg EPS beat(8)-194.4%

EPS beat(12)4

Avg EPS beat(12)-175.46%

EPS beat(16)7

Avg EPS beat(16)-142.82%

Revenue beat(2)0

Avg Revenue beat(2)-54.15%

Min Revenue beat(2)-65.56%

Max Revenue beat(2)-42.74%

Revenue beat(4)0

Avg Revenue beat(4)-89.99%

Min Revenue beat(4)-164.6%

Max Revenue beat(4)-42.74%

Revenue beat(8)0

Avg Revenue beat(8)-74.93%

Revenue beat(12)3

Avg Revenue beat(12)-47.3%

Revenue beat(16)7

Avg Revenue beat(16)-23.53%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.74
P/FCF	N/A
P/OCF	N/A
P/B	1.62
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2.19

EYN/A

EPS(NY)-0.57

Fwd EYN/A

FCF(TTM)-0.27

FCFYN/A

OCF(TTM)-0.27

OCFYN/A

SpS0.16

BVpS0.28

TBVpS-0.05

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-126.93%
ROE	-466.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-27.2%

ROA(5y)-16.24%

ROE(3y)-243.55%

ROE(5y)-147.96%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.16

Health

		Industry Rank	Sector Rank
Debt/Equity	0.45
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0.96%
Cap/Sales	0.87%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.96
Quick Ratio	0.93
Altman-Z	-4.5

F-Score3

WACC14.95%

ROIC/WACCN/A

Cap/Depr(3y)42.96%

Cap/Depr(5y)127.08%

Cap/Sales(3y)7.51%

Cap/Sales(5y)7.91%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-80.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.67%

EPS Next Y75.59%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-80.65%

Revenue growth 3Y-55.91%

Revenue growth 5Y-7.32%

Sales Q2Q%-49.6%

Revenue Next Year64.06%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-82.04%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year166.17%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-75.35%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-269.37%

OCF growth 3YN/A

OCF growth 5YN/A

PROPHASE LABS INC (PRPH) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens